These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2555874)

  • 61. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor.
    Brewer C; Bonin F; Bullock P; Nault MC; Morin J; Imbeault S; Shen TY; Franks DJ; Bennett SA
    J Neurochem; 2002 Sep; 82(6):1502-11. PubMed ID: 12354298
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A; Tahraoui L; Sedivy P; Cavero I
    J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardiovascular reactions and respiratory events during platelet activating factor-induced shock.
    Felix SB; Baumann G; Raschke P; Maus C; Berdel WE
    Basic Res Cardiol; 1990; 85(3):217-26. PubMed ID: 2383216
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [An experimental study on shock after temporary hepatic inflow occlusion and platelet activating factor (PAF)].
    Fukuoka T
    Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1596-602. PubMed ID: 2263243
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock.
    Lefer AM; Lefer DJ
    Annu Rev Pharmacol Toxicol; 1993; 33():71-90. PubMed ID: 8494355
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The role of the thrombocyte-activating factor in the development of circulatory disorders in the postischemic shock reaction].
    Sagach VF; Dmitrieva AV
    Fiziol Zh (1978); 1990; 36(4):8-14. PubMed ID: 2172032
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effects of PAF antagonists in experimental models. Therapeutical perspectives].
    Desquand S
    Therapie; 1993; 48(6):585-97. PubMed ID: 8091344
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs: protective effects of indomethacin.
    Mózes T; Zijlstra FJ; Heiligers JP; Tak CJ; Ben-Efraim S; Bonta IL; Saxena PR
    Br J Pharmacol; 1991 Nov; 104(3):691-9. PubMed ID: 1797328
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of the specific platelet-activating factor antagonists, BN 52021 and BN 52063, on various experimental gastrointestinal ulcerations.
    Braquet P; Etienne A; Mencia-Huerta JM; Clostre F
    Eur J Pharmacol; 1988 Jun; 150(3):269-76. PubMed ID: 3046952
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synthetic biotinylated peptide compounds derived from Asp-hemolysin: novel potent inhibitors of platelet-activating factor.
    Sato A; Kumagai T; Aoki J; Ebina K
    Eur J Pharmacol; 2012 Jun; 685(1-3):205-12. PubMed ID: 22542654
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Platelet-activating factor (PAF) and PAF antagonists in asthma.
    Hosford D; Mencia-Huerta JM; Braquet P
    Crit Rev Ther Drug Carrier Syst; 1990; 7(3):261-73. PubMed ID: 2073689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
    Albert DH; Magoc TJ; Tapang P; Luo G; Morgan DW; Curtin M; Sheppard GS; Xu L; Heyman HR; Davidsen SK; Summers JB; Carter GW
    Eur J Pharmacol; 1997 Apr; 325(1):69-80. PubMed ID: 9151941
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.
    Sörensen J; Kald B; Tagesson C; Lindahl M
    Intensive Care Med; 1994 Nov; 20(8):555-61. PubMed ID: 7706567
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia.
    Hsueh W; González-Crussi F; Arroyave JL
    FASEB J; 1987 Nov; 1(5):403-5. PubMed ID: 3678700
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PAF-antagonist administration after hemorrhage-resuscitation prevents splenocyte immunodepression.
    Zellweger R; Ayala A; Schmand JF; Morrison MH; Chaudry IH
    J Surg Res; 1995 Sep; 59(3):366-70. PubMed ID: 7643595
    [TBL] [Abstract][Full Text] [Related]  

  • 76. P-selectin-deficient mice are protected from PAF-induced shock, intestinal injury, and lethality.
    Sun X; Rozenfeld RA; Qu X; Huang W; Gonzalez-Crussi F; Hsueh W
    Am J Physiol; 1997 Jul; 273(1 Pt 1):G56-61. PubMed ID: 9252509
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The presence of platelet-activating factor-acetylhydrolase in human middle ear effusions.
    Tsuji H; Furukawa M; Ikeda H; Asako M; Yamashita T
    ORL J Otorhinolaryngol Relat Spec; 1998; 60(1):25-9. PubMed ID: 9519378
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Experimental studies on the relation of platelet activating factor (PAF) to high mortality in sublethal endotoxemia after massive hepatectomy and effects of its antagonist].
    Onuki Y; Nakamura S; Muro H; Baba S
    Nihon Geka Gakkai Zasshi; 1993 May; 94(5):466-74. PubMed ID: 8332121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation.
    Golino P; Ambrosio G; Ragni M; Pascucci I; Triggiani M; Oriente A; McNatt J; Buja LM; Condorelli M; Chiariello M
    Circulation; 1993 Sep; 88(3):1205-14. PubMed ID: 8353882
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.
    Travers JB; Rohan JG; Sahu RP
    Front Endocrinol (Lausanne); 2021; 12():624132. PubMed ID: 33796070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.